Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Biologics Inc.

Headquarters: Cary, NC, United States of America
Website: N/A
Year Founded: 1994
Status: Acquired

BioCentury | Apr 3, 2025
Product Development

Exosomes are finding new life as the field solves for manufacturing

Can exosomes step in as delivery vehicles where LNPs fall short?
BioCentury | Mar 29, 2025
Product Development

Bispecifics for I&I: Bypassing combination complexity

At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Mar 26, 2025
Data Byte

China deals look beyond cancer

At least eight East-to-West licensing deals outside oncology so far this year
BioCentury | Mar 18, 2025
Data Byte

Wuxi stocks bounce back as Biosecure threat fades

Shares of Wuxi Apptec and Wuxi Biologics are closing in on pre-Biosecure levels
BioCentury | Feb 26, 2025
Management Tracks

Lindsay Androski named CEO of Arbutus

Plus: CMO Maria Koehler steps down at Repare, and updates from Isomab, Crescent, Ottimo and Senti Bio
BioCentury | Feb 15, 2025
Management Tracks

Robert Michael to succeed Gonzalez as Abbvie’s chair

Plus: Olazábal leaving Ysios and updates from Augustine and Prolific
BioCentury | Jan 7, 2025
Deals

Irish sale from Wuxi Biologics, Roche looks to Innovent for ADC

BioCentury’s Deals Report: Wuxi Biologics, Hutchmed in asset sales and more
BioCentury | Dec 31, 2024
Finance

Biotech raises make 2024 the year of the PIPE

BioCentury’s final Public Equity Report of the year tallies up fundraising activity
BioCentury | Dec 31, 2024
Deals

Drumbeat of China deals steady through year-end

Wuxi Apptec moves to preserve its core interests, GLP-1R deals showcase breadth of China biotech’s dealmaking
BioCentury | Dec 9, 2024
Politics, Policy & Law

Biosecure setback amid lawmakers’ push to reduce reliance on China

Defense bill places biotech under national security umbrella
Items per page:
1 - 10 of 1252